VXRT
Vaxart, Inc.
$0.5600
-1.75%
No data for this timeframe.
Vol
Inst. Holders3 funds
Inst. Value$707.2K
Inst. Activity4 buys / 0 sells
Insider Activity1B / 0S
Insider Net $$6.5K
SEC Reports10
Press Releases2
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0000072444·Prev Close $0.5700
Recent Activity
Jun 8, 2026
SEC
Vaxart has filed definitive additional proxy soliciting materials (DEFA14A) urging shareholders to vote FOR all six of t
DEFA14A — Impact 4/10
Jun 8, 2026
SEC
Vaxart's management filed definitive additional proxy soliciting material urging shareholders to vote FOR all six manage
DEFA14A — Impact 4/10
Jun 1, 2026
SEC
Vaxart filed definitive additional proxy materials urging shareholders to vote FOR its six director nominees at the July
DEFA14A — Impact 5/10
May 22, 2026
Insider
Watson W. Mark bought 10,000 shares
Director @ $0.6530 ($6.5K)
May 19, 2026
Insider
Grasman Jeroen Nicolaas surrendered for taxes 31,395 shares
Chief Financial Officer @ $0.6100 ($19.2K)
May 7, 2026
earnings_calendar
VXRT Q1 2026 Earnings Scheduled — 2026-05-07
Apr 23, 2026
Insider
BREITMEYER JAMES B was granted 157,400 shares
Director
Inst.
UBS Group AG — ADD
825,758 shares ($373.2K)
Price Targets
Historical data — last covering-analyst action Mar 2025. No current recommendation available.
$3.00 (Mar 2025)
Current $0.5600
Low $2.00
Median $3.00
High $4.00
2 analysts
$2.00
$4.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 27, 2025 | B. Riley Securities | MAINTAIN | Buy → Buy |
| Aug 15, 2024 | Oppenheimer | INITIATE | Outperform |
| Jan 31, 2024 | B. Riley Securities | UPGRADE | Neutral → Buy |
| Sep 7, 2023 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Aug 7, 2023 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.21 | $-0.21 — $-0.21 | -200% YoY | 1 |
| Next Q | $-0.03 ▲ +50.0% | $-0.03 — $-0.03 | 25% YoY | 1 |
| Current FY | $0.06 ▲ +111.1% | $0.06 — $0.06 | -14% YoY | 1 |
| Next FY | $-0.68 ▼ -1.5% | $-0.68 — $-0.68 | -1233% YoY | 1 |
Latest Reports
NEUTRAL
DEFA14A
4/10
Vaxart has filed definitive additional proxy soliciting materials (DEFA14A) urging shareholders to vote FOR all six of t
Jun 8, 2026
NEUTRAL
DEFA14A
4/10
Vaxart's management filed definitive additional proxy soliciting material urging shareholders to vote FOR all six manage
Jun 8, 2026
NEUTRAL
Press
4/10
Vaxart announced a $25 million at-the-market equity financing facility with Lincoln Park Capital, allowing the company t
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MARSHALL WACE, LLP | $703.1K | TRIM |
| WEALTH ENHANCEMENT ADVISORY SERVICES, | $3.6K | — |
| Rockefeller Capital Management L.P. | $429.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Watson W. | BUY | $6.5K |
| May 19, 2026 | Grasman Jeroen | F | $19.2K |
| Apr 23, 2026 | BREITMEYER JAMES | A | $0.00 |
| Apr 23, 2026 | BREITMEYER JAMES | A | $0.00 |
| Mar 28, 2026 | Cummings James | F | $2.1K |
3 institutional holders with $707.2K total value (1,964,612 shares) as of 2025-Q3. Top holders: MARSHALL, WEALTH, Rockefeller.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 1,953,037 | $703.1K | 99.4% | TRIM -72.7% |
| 2 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 10,400 | $3.6K | 0.5% | — |
| 3 | Rockefeller Capital Management L.P. | 1,175 | $429.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | ADD | 559,206 | 825,758 | +47.7% | $373.2K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 606 | 223,866 | +36841.6% | $101.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 13,824 | 106,929 | +673.5% | $48.3K | 2025-Q2 |
| Corient Private Wealth LLC | DOUBLED | 19,825 | 39,650 | +100.0% | $17.9K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 280 | 606 | +116.4% | — | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 106,725 | 214,028 | +100.5% | $87.1K | 2025-Q1 |
| Invesco Ltd. | ADD | 75,798 | 146,366 | +93.1% | $59.6K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 184,447 | 121,641 | -34.1% | $49.5K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 51,683 | 13,824 | -73.3% | $5.6K | 2025-Q1 |
| UBS Group AG | DOUBLED | 318 | 495,793 | +155809.7% | $328.2K | 2024-Q4 |
| GROUP ONE TRADING LLC | ADD | 66,802 | 105,896 | +58.5% | $70.1K | 2024-Q4 |
| Invesco Ltd. | ADD | 50,995 | 75,798 | +48.6% | $50.2K | 2024-Q4 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 6,200 | 10,000 | +61.3% | $6.6K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 7,658 | 4,658 | -39.2% | $3.1K | 2024-Q4 |
| CITIGROUP INC | DOUBLED | 3 | 1,464 | +48700.0% | $969.00 | 2024-Q4 |
| FMR LLC | NEAR_EXIT | 2,609 | 185 | -92.9% | $122.00 | 2024-Q4 |
| ROYAL BANK OF CANADA | TRIM | 468 | 280 | -40.2% | — | 2024-Q3 |
| MARSHALL WACE, LLP | TRIM | 247,414 | 67,484 | -72.7% | $57.4K | 2024-Q3 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 22,556 | 28,600 | +26.8% | $24.3K | 2024-Q3 |
| HighTower Advisors, LLC | ADD | 11,905 | 21,805 | +83.2% | $17.0K | 2024-Q3 |
7 unique insiders with 27 transactions. Net insider value: $6.5K ($6.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Watson W. Mark | Director | BUY | 10,000 | $0.6530 | $6.5K |
| May 19, 2026 | Grasman Jeroen Nicolaas | Chief Financial Officer | TAX W/H | 31,395 | $0.6100 | $19.2K |
| Apr 23, 2026 | BREITMEYER JAMES B | Director | AWARD | 157,400 | — | — |
| Apr 23, 2026 | BREITMEYER JAMES B | Director | AWARD | 78,800 | — | — |
| Mar 28, 2026 | Cummings James F. | Chief Medical Officer | TAX W/H | 3,292 | $0.6500 | $2.1K |
| Mar 28, 2026 | Tucker Sean | SVP, Chief Scientific Officer | TAX W/H | 3,924 | $0.6500 | $2.6K |
| Mar 24, 2026 | Tucker Sean | SVP, Chief Scientific Officer | TAX W/H | 36,418 | $0.6940 | $25.3K |
| Mar 24, 2026 | Lo Steven | President, Chief Exec Officer | TAX W/H | 126,028 | $0.6940 | $87.5K |
| Mar 24, 2026 | Cummings James F. | Chief Medical Officer | TAX W/H | 30,551 | $0.6940 | $21.2K |
| Mar 24, 2026 | Berg Edward B | SVP, General Counsel | TAX W/H | 36,418 | $0.6940 | $25.3K |
| Mar 18, 2026 | Tucker Sean | SVP, Chief Scientific Officer | TAX W/H | 8,072 | $0.6346 | $5.1K |
| Mar 18, 2026 | Lo Steven | President, Chief Exec Officer | TAX W/H | 22,425 | $0.6346 | $14.2K |
| Mar 18, 2026 | Cummings James F. | Chief Medical Officer | TAX W/H | 6,772 | $0.6346 | $4.3K |
| Mar 18, 2026 | Berg Edward B | SVP, General Counsel | TAX W/H | 8,072 | $0.6346 | $5.1K |
| Mar 16, 2026 | Lo Steven | President, Chief Exec Officer | AWARD | 1,543,000 | — | — |
| Mar 16, 2026 | Tucker Sean | SVP, Chief Scientific Officer | AWARD | 410,000 | — | — |
| Mar 16, 2026 | Cummings James F. | Chief Medical Officer | AWARD | 455,000 | — | — |
| Mar 16, 2026 | Tucker Sean | SVP, Chief Scientific Officer | AWARD | 200,000 | — | — |
| Mar 16, 2026 | Berg Edward B | SVP, General Counsel | AWARD | 115,000 | — | — |
| Mar 16, 2026 | Grasman Jeroen Nicolaas | Chief Financial Officer | AWARD | 455,000 | — | — |
| Mar 16, 2026 | Berg Edward B | SVP, General Counsel | AWARD | 225,000 | — | — |
| Mar 16, 2026 | Cummings James F. | Chief Medical Officer | AWARD | 227,000 | — | — |
| Mar 16, 2026 | Grasman Jeroen Nicolaas | Chief Financial Officer | AWARD | 227,000 | — | — |
| Mar 16, 2026 | Lo Steven | President, Chief Exec Officer | AWARD | 846,500 | — | — |
| Feb 2, 2026 | Tucker Sean | SVP, Chief Scientific Officer | TAX W/H | 9,265 | $0.6085 | $5.6K |
| Feb 2, 2026 | Cummings James F. | Chief Medical Officer | TAX W/H | 7,965 | $0.6085 | $4.8K |
| Feb 2, 2026 | Berg Edward B | SVP, General Counsel | TAX W/H | 9,265 | $0.6085 | $5.6K |
10 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 7 neutral. Avg impact: 4.7/10.
NEUTRAL
DEFA14A
4/10
Vaxart has filed definitive additional proxy soliciting materials (DEFA14A) urging shareholders to v
Jun 8, 2026
NEUTRAL
DEFA14A
4/10
Vaxart's management filed definitive additional proxy soliciting material urging shareholders to vot
Jun 8, 2026
NEUTRAL
DEFA14A
5/10
Vaxart filed definitive additional proxy materials urging shareholders to vote FOR its six director
Jun 1, 2026
NEUTRAL
DEFA14A
4/10
Vaxart filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting,
May 20, 2026
NEUTRAL
DEFA14A
4/10
Vaxart filed additional definitive proxy soliciting materials in connection with its 2026 Annual Mee
May 20, 2026
NEUTRAL
PREC14A
4/10
Vaxart filed a preliminary proxy statement for its 2026 annual meeting, facing a contested director
May 19, 2026
MIXED
DEFA14A
6/10
Vaxart filed preliminary proxy materials and issued an open letter to shareholders ahead of its July
May 19, 2026
BEARISH
PRESS-RELEASE
7/10
Vaxart reported a significant Q4 2025 EPS miss of -$0.10 versus the $0.02 consensus, a 600% negative
May 1, 2026
NEUTRAL
8-K
3/10
Vaxart, Inc. announced a lease amendment to expand its facilities by adding approximately 3,531 rent
Apr 21, 2026
BEARISH
8-K
6/10
Vaxart entered into a $25 million equity line agreement with Lincoln Park Capital, allowing it to se
Apr 17, 2026
Historical analyst distribution (last covering-analyst action Mar 2025): 88% buy across 8 analysts — 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2025. No current recommendation available.
$3.00 mean target (Mar 2025)
$2.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5600 |
| Target Low | $2.00 |
| Target Mean | $3.00 |
| Target Median | $3.00 |
| Target High | $4.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.21 | $-0.21 | $-0.21 | -200.0% | — | — | $0.1B | 27.1% | 1 |
| Next Q 2026-09-30 |
$-0.03 | $-0.03 | $-0.03 | 25.0% | +50.0% | — | $0.1B | -30.3% | 1 |
| Current FY 2026-12-31 |
$0.06 | $0.06 | $0.06 | -14.3% | +111.1% | 0↑ 1↓ | $0.4B | 50.0% | 1 |
| Next FY 2027-12-31 |
$-0.68 | $-0.68 | $-0.68 | -1233.3% | -1.5% | 0↑ 1↓ | $0.0B | -100.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.210 | |
| 7d ago | $0.000 | -0.210 |
| 30d ago | $0.000 | -0.210 |
| 60d ago | $0.000 | -0.210 |
| 90d ago | $0.000 | -0.210 |
6 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 27, 2025 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Aug 15, 2024 | Oppenheimer | INITIATE | — | Outperform |
| Jan 31, 2024 | B. Riley Securities | UPGRADE | Neutral | Buy |
| Sep 7, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 7, 2023 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Dec 19, 2022 | B. Riley Securities | MAINTAIN | — | Neutral |
| Sep 2, 2022 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| May 19, 2022 | B. Riley Securities | MAINTAIN | — | Neutral |
| Nov 2, 2021 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Jun 30, 2021 | B. Riley Securities | DOWNGRADE | Buy | Neutral |
| Jun 24, 2021 | Jefferies | INITIATE | — | Buy |
| Jun 11, 2021 | Piper Sandler | INITIATE | — | Overweight |
| Aug 12, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jul 13, 2020 | B. Riley Securities | INITIATE | — | Buy |
| Apr 30, 2020 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jun 27, 2019 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
VXRT Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings_calendar
VXRT Q1 2026 Earnings Scheduled — 2026-05-06
May 1, 2026
earnings
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
<p align="center"><em>Company to report first quarter 2026 financial results on May 7</em></p>
Apr 23, 2026
other
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
<p align="center"><em>Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform</em><
Apr 17, 2026
regulatory
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
<p>SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotech
Mar 12, 2026
earnings_calendar
VXRT Q4 2025 Earnings After Market Close — 2026-03-12
Mar 3, 2026
earnings
Vaxart to Host Upcoming Conference Calls
<p align="center"><em>Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET</em></p>